Skip to main content
Signal8
Launch Terminal

Nyxoah SA (NYXH)

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Specialties

Nyxoah S.A. logo

Nyxoah S.A.

NASDAQ:NYXHHealthcare
-1.85%$0.8715
AH$0.8715+0.00%vs close
Mkt Cap$87.21M
Float75.94M
O/S100.07M
Vol
$ Vol
RVOL
Inst Own22.6%
SI0.3%
Earnings
Dilution
Nyxoah S.A. logoNASDAQ:NYXH$0.8715-1.85%
Phase Distribution
8 lead-sponsored trials·4 active·1 completed
Not applicable8
Status Overview
Not yet recruiting1
Recruiting1
Active, not recruiting3
Completed1
Stopped2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
  • Not applicable
    Terminated

    Safety and Performance Study of the Nyxoah SAT System for Treating OSA

    Nyxoah SAT system

    Obstructive Sleep Apnea

    Enrollment
    6
    Start
    Dec 2014
    Primary Completion
    Nov 2015
    Completion
    Apr 2016
    NCT02312479
  • Not applicable
    Completed

    BiLAteral Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnoea (BLAST OSA)

    Genio(TM) bilateral hypoglossal nerve stimulation system

    Obstructive Sleep Apnea of Adult

    Enrollment
    27
    Start
    Mar 2017
    Primary Completion
    Sep 2018
    Completion
    Sep 2018
    NCT03048604
  • Not applicable
    Terminated

    BilatEral Hypoglossal Nerve StimulaTion for TreatmEnt of ObstRuctive SLEEP Apnoea With and Without Complete Concentric Collapse

    Genio(TM) bilateral hypoglossal nerve stimulation system

    Obstructive Sleep Apnea

    Enrollment
    42
    Start
    Jan 2019
    Primary Completion
    Jun 2021
    Completion
    Jun 2024
    NCT03763682
  • Not applicable
    Active, not recruiting

    Dual-sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea (DREAM)

    Genio™ system

    Obstructive Sleep Apnea

    Enrollment
    115
    Start
    Oct 2020
    Primary Completion
    Feb 2024
    Completion
    Feb 2028est.
    NCT03868618
  • Not applicable
    Active, not recruiting

    A Post-market Clinical Follow up of the Genio® System for the Treatment of Obstructive Sleep Apnea in Adults

    Genio® system therapy

    Obstructive Sleep Apnea

    Enrollment
    110
    Start
    Sep 2019
    Primary Completion
    Oct 2026est.
    Completion
    Oct 2030est.
    NCT04031040
  • Not applicable
    Active, not recruiting

    Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.

    Genio System

    Sleep Apnea, Obstructive

    Enrollment
    124
    Start
    Dec 2022
    Primary Completion
    Sep 2026est.
    Completion
    Sep 2028est.
    NCT05592002
  • Observational
    Not yet recruiting

    An Extension Study to Assess the Long-term Safety of the Genio® System

    Genio System

    Obstructive Sleep Apnea of Adult

    Enrollment
    39
    Start
    Nov 2025est.
    Primary Completion
    Jul 2029est.
    Completion
    Jul 2029est.
    NCT05939141
  • Observational
    Recruiting

    Bi-lateral HGN Therapy in Real-World Patients -Post Approval Research Investigation

    This is a single arm study, all consented and eligible subjects will be implanted with the Genio® System 2.1

    Obstructive Sleep Apnea

    Enrollment
    229
    Start
    Jun 2026est.
    Primary Completion
    Oct 2028est.
    Completion
    Oct 2032est.
    NCT07331285
Search ClinicalTrials.gov for “Nyxoah”